Description

Febuxostat is a selective, non?purine xanthine oxidase inhibitor that reduces uric acid production. It has been widely prescribed to manage elevated uric acid in gout patients, particularly when allopurinol is inadequate . This research-grade product, branded Nobetán, is manufactured by Zhejiang Node Pharmaceutical Co., Ltd., and approved under NMPA registration H20233826, with drug code 86983521000226 and barcode 6974198633989.

Each box contains 4 blister packs (7?×?80?mg tablets). Not for therapeutic or diagnostic use—strictly for pre?clinical studies, biochemical assays, xanthine oxidase activity tests, and gout-model research.

Product Specifications

Mechanism & Research Applications

Febuxostat selectively inhibits xanthine oxidase, reducing uric acid formation by blocking hypoxanthine/xanthine metabolism—a mechanism valuable in gout and hyperuricemia research . Possible research uses include:

• Xanthine oxidase biochemical assays

• Uric acid synthesis pathway studies

• Models of gout and kidney stone formation

• Preclinical evaluation of purine metabolism modulators

Safety & Handling

• Intended Use: Research only—not for clinical or veterinary use

• Storage: Store sealed and protected from moisture/light, below 30?°C

• Handling: Use lab PPE (gloves, goggles, lab coat)

• Disposal: Follow institutional safety protocols for chemical/biological waste

Core Keywords

Febuxostat tablets, Nobetán tablets, febuxostat 80?mg, xanthine oxidase inhibitor, gout research compound, laboratory febuxostat, NMPA H20233826 febuxostat, Zhejiang Node Pharmaceutical febuxostat, wholesale febuxostat tablets, preclinical uric acid inhibitor

Research Use Disclaimer

This product is strictly for laboratory research use and not approved for any clinical, therapeutic, diagnostic, or veterinary application. Improper use may pose safety risks. Ensure compliance with institutional biosafety regulations and local guidelines.